^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    SYHA1813

    i
    Other names: SYHA1813
    Associations

    News

    Trials
    Company:
    CSPC Pharma, Shanghai Inst. of Materia Medica
    Drug class:
    VEGFR inhibitor, CSF-1R inhibitor
    Related drugs:
    Associations

    News

    Trials
    5ms
    Relative Bioavailability and Food Effect of SYHA1813 Oral Solution in Healthy Participants (clinicaltrials.gov)
    P1, N=18, Not yet recruiting, Shanghai Runshi Pharmaceutical Technology Co., Ltd
    New P1 trial
    |
    SYHA1813
    5ms
    Preclinical and early clinical studies of a novel compound SYHA1813 that efficiently crosses the blood-brain barrier and exhibits potent activity against glioblastoma. (PubMed, Acta Pharm Sin B)
    SYHA1813 also displayed potent in vivo antitumor activity against GBM in immune-competent and immune-deficient mouse models, including temozolomide (TMZ) insensitive tumors. As a clinical proof of concept, SYHA1813 achieved confirmed responses in patients with recurrent GBM in an ongoing first-in-human phase I trial. The data of this study support the rationale for an ongoing phase I clinical study (ChiCTR2100045380).
    Preclinical • Journal
    |
    CSF1R (Colony stimulating factor 1 receptor)
    |
    temozolomide • SYHA1813
    10ms
    A phase I dose-expansion cohort of SYHA1813, a vascular endothelial growth factor receptor (VEGFR) 1-3 /colony-stimulating factor 1 receptor (CSF1R) inhibitor, in patients (pts) with recurrent meningioma (ESMO 2023)
    No grade-5 TEAEs were reported. Conclusions SYHA1813 showed encouraging objective responses with a well-tolerated safety profile in pts with recurrent meningioma.
    P1 data
    |
    FLT1 (Fms-related tyrosine kinase 1) • CSF1R (Colony stimulating factor 1 receptor)
    |
    SYHA1813
    1year
    A phase I dose-escalation study of SYHA1813, a VEGFR and CSF1R inhibitor, in patients with recurrent High-Grade Gliomas or Advanced Solid Tumors. (PubMed, Invest New Drugs)
    The toxicities of SYHA1813 were manageable, and encouraging antitumor efficacy was observed in patients with recurrent malignant glioma. This study is registered with the Chinese Clinical Trial Registry ( www.chictr.org.cn/index.aspx ; identifier ChiCTR2100045380).
    P1 data • Clinical Trial,Phase I • Journal • Metastases
    |
    KDR (Kinase insert domain receptor) • CSF1R (Colony stimulating factor 1 receptor)
    |
    SYHA1813